[Drug-induced glomerular nephropathies].
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D003630:Daunorubicin / Q000009:adverse effects; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D006046:Gold / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000276:immunology; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000276:immunology; D008094:Lithium / Q000009:adverse effects; D008628:Mercury / Q000009:adverse effects; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects; D051381:Rats; D011919:Rats, Inbred Strains; D013438:Sulfhydryl Compounds / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D008937:Mitomycins; D013438:Sulfhydryl Compounds; D016685:Mitomycin; D006046:Gold; D004317:Doxorubicin; D008094:Lithium; D008628:Mercury; D003630:Daunorubicin
Néphropathies glomérulaires médicamenteuses.